A295 underwent breast reduction (5 PRINEO* and 5 SOC). Data were collected for surgery through post-op care. Data Observation Forms were designed based on information obtained from staff interviews. Activities were observed for which differences in time and supplies between PRINEO* and SOC were expected: incision closure, dressing application, and dressing changes. RESULTS: In Germany, average time for skin layer closure was 3.47 min with PRINEO* vs. 16.67 min for SOC. Average wound length was 57 cm vs. 54 cm, respectively, translating into higher speed of closure with PRINEO* (16.50 cm/min) compared to SOC (3.22 cm/min). Overall time for wound closure was similar in both arms due to increased time for dermal layer closure with PRINEO* (42 min). In the Netherlands, average time for skin layer closure was 1.57 min for PRINEO* vs. 15.83 min for SOC. Average wound length was 48 cm vs. 49 cm, respectively, translating into a speed of closure with PRINEO* of 30.74 cm/ min compared to 3.11 cm/min with SOC. Time for dermal and skin layer closure combined was lower for PRINEO* (13.47 min vs. 29.93 min). For dressing application and post-op dressing changes, SOC required on average 18.28 min in Germany and 3.95 min in the Netherlands. Additionally, the use of 1.2 PRINEO* units on average resulted in the elimination of sutures and dressings in both centres. CONCLU-SIONS: In one German and Dutch centre, the use of PRINEO* lead to increased skin closure speed and avoided time and supplies associated with dressing application and changes, at the expense of an average 1.2 PRINEO* units.
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PIH26 TREATMENT DURATION AND PRESCRIPTION REFILL RATE FOR VAGINAL ESTROGEN THERAPY IN MEDICAID ENROLLED WOMEN WITH ATROPHIC VAGINITIS
Neidecker MV 1 , Camacho F 2 , Balkrishnan R 3 1 Ohio State University, Columbus, OH, USA, 2 Penn State College of Medicine, Hershey, PA, USA, 3 University of Michigan, Ann Arbor, MI, USA OBJECTIVES: Among the two most frequently prescribed forms of vaginal estrogen (VE), acceptability of tablets has been shown to be greater than creams in clinical trials. However, creams are more often prescribed. This study examines the association between form of VE and initial prescription refill rate and treatment duration among Medicaid enrollees. METHODS: A retrospective cohort study was conducted using North Carolina Medicaid claims January 2003 to December 2007 of women ages 18-64 with a new VE prescription claim. Multiple logistic regression was performed to assess the association of VE form and initial prescription refill among women with 1 year post-index continuous enrollment; OLS regression was used to assess treatment duration over 2 years follow-up. Demographic factors included age and race. Additional covariates: Charlson-Deyo comorbidity index, number of outpatient visits, mammography, and systemic estrogen use in the pretreatment year, and index year. RESULTS: A total of 1812 patients prescribed VE (mean age 49.4 10.5, 30.9% black) having 1 year follow-up were identified; 465 women had 2 years follow-up. 89.6% received cream; 10.4% tablets. Initial prescription refill rate was 48.7% for tablets, 33.7% for cream (p 0.001). Average treatment duration among women with 1 refill and 2 years follow-up was longer for tablets than cream (291.7 214.3 days versus 281.8 226.3; p 0.745). Tablet users were significantly more likely to refill their initial prescription (OR 1.88, 95%CI 1.38-2.56). OLS regression results showed no significant difference in treatment duration for tablets vs. cream (beta 17.53, . CONCLUSIONS: This analysis of Medicaid claims showed tablet users were significantly more likely to refill their initial prescription than cream users. During 2 years of follow-up, treatment duration among those who refilled at least once was longer for tablet users, although not significant. These results give some real world support for women's greater acceptability of vaginal tablets to creams. A study was performed to determine quality of life (QoL) and utility scores associated with 3 stages of menopause: pre-menopause, perimenopause and post-menopause. METHODS: A cross-sectional study was conducted in Canada to determine the quality of life and utility scores associated with each stage of menopause as listed above. Women age 48-54 were recruited through primary care practices. The Menopause-Specific Quality of Life Questionnaire (MENQOL), a non-preferencebased QoL measure, included 29 items from 4 domains. Two preference-based tools were applied: Health Utilities Index Mark-3 (HUI-3) with 8 domains as an indirect measure of utility and a visual analogue scale (VAS) as a direct measure of disutility for menopausal symptoms. Mean and standard deviations (SD) were reported. Spearman's-rho test was applied for correlation between the various tools. Multiple regression analyses were performed to assess if demographic characteristics predicted scores on any of the measures, including individual MENQOL symptom scores. RESULTS: A total of 403 female subjects were recruited from 11 primary care practices in 4 provinces; 60% were employed and 63% had completed college. The mean MENQOL symptom scores ranged 3.1(SD 2.0) to 3.4(SD 2.1) out of 8. Specific MENQOL scores ranged 2.1-2.7, 3.0-3.6 and 3.4-3.9 for pre-, peri-and post-menopause respectively. HUI-3 scores were 0.83, 0.78 and 0.74 for the same sequence [overall 0.77 (SD 0.25)], and disutility scores with the VAS were 0.22, 0.37 and 0.37. The MENQOL vasomotor, psychological, physical and sexual domain scores correlated significantly with both VAS and HUI-3 scores (p 0.001). Some demographic variables were associated with certain domains of the MENQOL or the HUI-3; however, no significant associations were noted for age or education. Significant differences existed in utility scores between pre-and post-menopause. CONCLUSIONS: Of the three menopause subgroups investigated, the pre-menopause group was associated with the best QoL; QoL did not differ significantly between peri-and post-menopause.
PIH27 HEALTH RELATED QUALITY OF LIFE AND UTILITY SCORES IN MENOPAUSAL WOMEN
PIH28
VALIDATION OF THE SF-36 IN PATIENTS WITH ENDOMETRIOSIS
Stull D 1 , Wasiak R 1 , Kreif N 1 , Colligs A 2 , Seitz C 2 , Gerlinger C 2 1 United BioSource-Europe, London, UK, 2 Bayer Schering Pharma AG, Berlin, Germany OBJECTIVES: Endometriosis is a common, chronic gynaecological disease among women of reproductive age. Understanding treatment effects for endometriosis is critical for benefitting the health of women with this condition. The SF-36 has utility for understanding this condition because of some of its subscale focus (pain) and its ability to compare across diseases and populations. The SF-36 is one of the most common health measures used in studies of endometriosis; however, it has not been validated for this disease. The goal of this study was to assess validity of the SF-36 for endometriosis. METHODS: Using data from two clinical trials (N 252 & 198) of treatment for endometriosis, a full complement of psychometric analyses was performed. Additional instruments included a pelvic pain VAS and a clinical global impression of change (CGI-C). Analyses were conducted using Stata 10.1 and Mplus 5.1. RESULTS: Factor analyses confirmed the standard 8-subscale and 2-component factor structure of the SF-36 (CFI 0.94 and 0.93 for the two trials). The Bodily Pain (BP) subscale and the PCS were both moderately correlated with the pain VAS at baseline and over time (r 0.37 to 0.62; p 0.001). Change in BP and PCS correlated with the CGI-C (r 0.30 & 0.43; p 0.001): those who had the greatest change in BP and PCS also reported the greatest change on CGI-C. Other subscales (Role Physical, General Health, Vitality, Social Functioning) showed smaller correlations with change in the pain VAS and CGI-C. CONCLUSIONS: The SF-36 -particularly BP and the PCS-is sensitive to differences in patient pain and change in pain experience in endometriosis. The BP subscale and the PCS were dimensions of the SF-36 that showed consistent sensitivity to pain differences and change; however, other SF-36 subscales were significantly, but less strongly, related to differences in severity and changes in pain.
PIH29 VALIDATION AND CROSS-NATIONAL EQUIVALENCE OF THE EYELASH SATISFACTION QUESTIONNAIRE
Burgess SM 1 , Hansen JE 2 , Cole JC 3 , Dang J 4 1 Allergan, Inc, Irvine, CA, USA, 2 Allergan, Inc., Irvine, CA, USA, 3 Independent Consultant, Torrance, CA, USA, 4 Consulting Measurement Group, Torrance, CA, USA OBJECTIVES: The Eyelash Satisfaction Questionnaire (ESQ) has demonstrated its validity among adults in the US, but cross-national equivalence has not been documented. This study was conducted to examine the face and content validity and psychometric properties of the ESQ in an English speaking country in Europe, as well as to determine the cross-national equivalence. METHODS: Two focus groups (n 16) were conducted in the UK to examine the validity of the conceptual framework, as well as face and content validity, of the ESQ. Classical Test Theory (CTT) and latent variable modeling techniques were performed using data collected from the web survey in the UK. Confirmatory Factor Analysis (CFA), Multiple Group Structural Equation Modeling (MG-SEM), and Differential Item Functioning (DIF) were performed to examine the accuracy and stability of the three domains between US (n 909) and UK samples (n 605). RESULTS: Qualitative analysis of the focus group discussions supported the face and content validity of the ESQ and indicated that the conceptual framework established in the UK was similar to the framework established in the US. Internal consistency was found to be high across all three domains (Cronbach's 0.90, 0.91, 0.77) and item-to-domain correlations were high (0.55-0.84). The factor structure found in the original survey fit the data well with factor loadings ranging from 0.64 to 93. Measurement invariance models provided good fit to the data (NNFI 0.97, RMSEA 0.04). No significant DIF was found between the two samples (p's 0.05) and effect sizes of the differences were small (Cohen's d's 0.10). CON-CLUSIONS: The current research findings suggest that the ESQ has appropriate face and content validity and psychometric properties for use in the UK. It also provides support for the cross-national equivalence of the ESQ.
PIH30 SYMPTOMS AND IMPACT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD): CONCEPTS AND MEASUREMENT
Rofail D 1 , Abetz L 1 , Lindemann M 2 , Filonenko A 2 , Colligs A 2 , Endicott J 3 1 Mapi Values Ltd, Bollington, Cheshire, UK, 2 Bayer Schering Pharma AG, Berlin, Germany, 3 Columbia Univeristy College of Physicians and Surgeons, New York, NY, USA OBJECTIVES: To investigate the symptoms and impact associated with premenstrual dysphoric disorder (PMDD), and the appropriateness of the patient-reported Daily Record of Severity of Problems (DRSP) as an instrument to assess PMDD. METHODS: A review of 47 published peer-review articles and conference presentations was conducted to aid the development of a PMDD conceptual model. The content of the DRSP was then compared to the conceptual model to assess face and content validity. The
